Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

We may use terms like cold and the flu as if they are the same thing, but there are some key differences between them.

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

RSV primarily affects children and older adults, and can lead to severe illness or death. Severe illness from respiratory syncytial virus (RSV) can be prevented by administration of prophylactic ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events.

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...